Gut microbiota: impacts on gastrointestinal cancer immunotherapy

Gut Microbes

Jun Yu¹  Joseph Jao-Yiu Sung¹  Harry Cheuk Hay Lau¹ 

[1] State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, CUHK Shenzhen Research Institute, the Chinese University of Hong Kong;

关键词: gut microbiota;    gastrointestinal cancer;    adoptive cell transfer;    immune checkpoint blockade;    blockade-induced adverse events;    cpg-oligodeoxynucleotide therapy;    probiotics;    fecal microbiota transplantation;   

DOI  :  10.1080/19490976.2020.1869504

来源: DOAJ

【 摘 要 】

The association of gut microbiota with gastrointestinal carcinogenesis has been heavily investigated since the recent advance in sequencing technology. Accumulating evidence has revealed the critical roles of commensal microbes in cancer progression. Given by its importance, emerging studies have focussed on targeting microbiota to ameliorate therapeutic effectiveness. It is now clear that the microbial community is closely related to the efficacy of chemotherapy, while the correlation of microbiota with immunotherapy is much less studied. Herein, we review the up-to-date findings on the influence of gut microbiota on three common immunotherapies including adoptive cell transfer, immune checkpoint blockade, and CpG-oligodeoxynucleotide therapy. We then explore three microbiota-targeted strategies that may improve treatment efficacy, involving dietary intervention, probiotics supplementation, and fecal microbiota transplantation.

【 授权许可】

Unknown